Domača stranUCBJF • OTCMKTS
add
UCB SA
Prejšnji trg. dan.
174,00 $
Letni razpon
73,54 $ - 194,76 $
Tržna kapitalizacija
35,45 mrd. EUR
Povprečni obseg
66,00
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
EBR
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (EUR) | jun. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 1,40 mrd. | 10,80 % |
Stroški poslovanja | 807,00 mio. | 23,77 % |
Čisti dohodek | 104,00 mio. | −33,12 % |
Čista dobičkovnost prihodkov | 7,45 | −39,68 % |
Earnings per share | — | — |
EBITDA | 322,00 mio. | −11,54 % |
Efektivna davčna stopnja | 15,45 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (EUR) | jun. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 428,00 mio. | −6,35 % |
Skupna sredstva | 15,63 mrd. | 1,61 % |
Skupne obveznosti | 6,68 mrd. | 5,30 % |
Celoten lastniški kapital | 8,95 mrd. | — |
Shares outstanding | 189,72 mio. | — |
Razmerje P/B | 3,69 | — |
Donosnost sredstev | 2,61 % | — |
Donosnost kapitala | 3,40 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (EUR) | jun. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 104,00 mio. | −33,12 % |
Denar iz dejavnosti | 188,50 mio. | 51,41 % |
Denar iz naložb | −85,00 mio. | 37,73 % |
Denar iz financiranja | −317,50 mio. | −73,02 % |
Neto sprememba denarnih sredstev | −216,50 mio. | −7,44 % |
Prost denarni tok | 138,19 mio. | −22,61 % |
Vizitka
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
Generalni direktor
Datum ustanovitve
18. jan. 1928
Spletno mesto
Zaposleni
9.000
